Finally, Protagonist Therapeutics (NASDAQ:PTGX) has indicated that its financial runway extends beyond the fourth quarter of 2028, providing the company with a stable foundation to continue its ...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine ...
After a Stage 4 cancer diagnosis and a prognosis of 16 months to live, Katie Doble didn’t know whether she should plan her ...
Collaboration to take Cytovation’s synthetic peptide, CY-101, into a Phase 2 trial for patients with adrenocortical carcinomaCancer Research UK’s Centre for Drug Development to run the trial at sites ...
Research has introduced daromun, therapeutic vaccines, and novel combinations for metastatic melanoma, reshaping the ...
NDAQ:ZLAB) Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell ...
One of the earliest proponents of evidence-based medicine, Professor David Sackett, wrote, “Good doctors use both individual ...
Celldex Therapeutics , Inc. (NASDAQ:CLDX), a biopharmaceutical company with a market capitalization of $1.6 billion focused on developing innovative therapies for challenging diseases, has been making ...
In an interview, Danielle Mitchell of BWICR discussed the importance of increasing diversity in clinical research and making ...
Stuart Therapeutics completed a Phase 3 trial for ST-100, a treatment for dry eye disease, involving a randomized, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback